ArticleMedicine2025
A relapsed/refractory acute promyelocytic leukemia achieving complete response after chemotherapy with venetoclax.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleThe vast majority of patients newly diagnosed with acute promyelocytic leukemia (APL) can achieve complete response (CR) through induction therapy that includes all-trans retinoic acid (ATRA), and subsequently achieve molecular response after consolidation therapy. Relapses are quite rare after achieving molecular response. Nonetheless, 5% to 10% of APL patients who receive ATRA plus anthracycline chemotherapy may experience relapse. Compared to newly diagnosed APL patients, the treatment of relapsed/refractory APL remains a challenge due to its rarity. This article reports a case of an APL patient with multiple relapses who achieved complete response following chemotherapy with venetoclax (VEN) in combination with idarubicin and cytarabine. PATIENT CONCERNS: The patient is a 58-year-old male who was definitively diagnosed with acute promyelocytic leukemia 20 years ago. One month ago, he presented with gum bleeding. A bone marrow examination revealed that abnormal promyelocytes accounted for 58.0%, and a complete blood count indicated pancytopenia. DIAGNOSES: The patient has a definitive diagnosis of relapsed/refractory APL, complicated by a DNMT3A mutation and complex karyotype, indicating a poor prognosis.
interventionsComplete response was achieved after the salvage chemotherapy, specifically: VEN 100 mg day 4, 200 mg day 5, 400 mg days 6-11; Idarubicin 20 mg days 1-2; Cytarabine 100 mg bid days 1-5. OUTCOMES: After VEN-based therapy, the patient exhibited no symptoms of leukemia and had achieved complete response. LESSONS: For relapsed and refractory APL, relevant drug resistance gene monitoring should be carried out. Some relapsed and refractory APL patients who do not respond to conventional treatment are at risk of death. We report a successful case, the regimen of VEN targeted therapy combined with chemotherapy still holds promise for the treatment of future relapsed/refractory APL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.